164
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Association of Pre-Existing Comorbidities with Disease Severity Among COVID-19 Patients in Eastern Ethiopia

ORCID Icon, ORCID Icon, ORCID Icon, , , , ORCID Icon & ORCID Icon show all
Pages 2825-2834 | Published online: 01 Jun 2022

References

  • Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020;10:10.1016.
  • Guan W-J, Liang W-H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020
  • Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574–1581. doi:10.1001/jama.2020.5394
  • Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. doi:10.1016/S0140-6736(20)31189-2
  • Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943. doi:10.1001/jamainternmed.2020.0994
  • Schuetz P, Castro P, Shapiro NI. Diabetes and sepsis: preclinical findings and clinical relevance. Diabetes Care. 2011;34(3):771–778. doi:10.2337/dc10-1185
  • Jakovac H. COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome? Am J Physiol Heart Circulat Physiol. 2020;319(4):H793–H796. doi:10.1152/ajpheart.00506.2020
  • Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allerg Clin Immunol. 2020;146(1):110–118. doi:10.1016/j.jaci.2020.04.006
  • Baradaran A, Ebrahimzadeh MH, Baradaran A, Kachooei AR. Prevalence of comorbidities in COVID-19 patients: a systematic review and meta-analysis. Archiv Bone Joint Surg. 2020;8(Suppl 1):247. doi:10.22038/abjs.2020.47754.2346
  • Sanyaolu A, Okorie C, Marinkovic A, et al. Navigating the diagnostics of COVID-19. SN Comprehens Clin Med. 2020;2(9):1393–1400. doi:10.1007/s42399-020-00408-8
  • World Health Organization. Food, medicine and healthcare administration and control authority of Ethiopia. In: Standard Treatment Guidelines for General Hospital. World Health Organization; 2015.
  • National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Clinical Spectrum of SARS-CoV-2 Infection. USA: National Institutes of Health. 2021:48-56.
  • Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
  • Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
  • Liu K, Fang -Y-Y, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133(9):1025. doi:10.1097/CM9.0000000000000744
  • Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metabol Syndr Clin Res Rev. 2020;14(4):303–310. doi:10.1016/j.dsx.2020.04.004
  • Shaikh FS, Aldhafferi N, Buker A, et al. Comorbidities and risk factors for severe outcomes in COVID-19 patients in Saudi Arabia: a retrospective cohort study. J Multidiscip Healthc. 2021;14:2169. doi:10.2147/JMDH.S317884
  • Khan A, Althunayyan S, Alsofayan Y, et al. Risk factors associated with worse outcomes in COVID-19: a retrospective study in Saudi Arabia. East Mediterran Health J. 2020;26:11. doi:10.26719/emhj.20.130
  • Moni MA, Liò P. Network-based analysis of comorbidities risk during an infection: SARS and HIV case studies. BMC Bioinform. 2014;15(1):1–23. doi:10.1186/1471-2105-15-333
  • Morais-Almeida M, Pité H, Aguiar R, Ansotegui I, Bousquet J. Asthma and the coronavirus disease 2019 pandemic: a literature review. Int Arch Allergy Immunol. 2020;181(9):680–688. doi:10.1159/000509057
  • Muhamad S-A, Ugusman A, Kumar J, Skiba D, Hamid AA, Aminuddin A. COVID-19 and hypertension: the what, the why, and the how. Front Physiol. 2021;12:589. doi:10.3389/fphys.2021.665064
  • Zhu L, She Z-G, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068–1077. e1063. doi:10.1016/j.cmet.2020.04.021
  • Kralj M, Jakovac H. Vitamin D and COVID-19 in an immunocompromised patient with multiple comorbidities—a case report. Clin Case Rep. 2021;9(4):2269–2275. doi:10.1002/ccr3.4010
  • Mohammad S, Aziz R, Al Mahri S, et al. Obesity and COVID-19: what makes obese host so vulnerable? Immun Ageing. 2021;18(1):1–10. doi:10.1186/s12979-020-00212-x
  • Abu-Farha M, Al-Mulla F, Thanaraj TA, et al. Impact of diabetes in patients diagnosed with COVID-19. Front Immunol. 2020;10:3112. doi:10.3389/fimmu.2019.03112
  • Yang X, Yang X, Kumar P, Cao B, Ma X, Li T. Social support and clinical improvement in COVID-19 positive patients in China. Nurs Outlook. 2020;68(6):830–837. doi:10.1016/j.outlook.2020.08.008